Testing a new drug for advanced cancers with BRAF changes
Treatments studied
Part of Cancer, Hormones & metabolism, Lungs & breathing, Skin clinical trials.
This Phase 1 trial studies PF-07799933, a new medicine, in people whose advanced solid tumors have specific BRAF genetic changes. It may help if your cancer has continued to grow after standard treatments, and there may be specific options depending on your cancer type and past therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an advanced or metastatic solid tumor (tumors that have spread), including certain brain tumors
- Your tumor (or blood test) shows a qualifying BRAF change, either V600 or certain non-V600 types
- Your cancer has gotten worse during or after your most recent treatment, with no other good options
- You must have had the specific prior treatments required for your cancer type and study “cohort”
- If you have brain metastases, the largest one must be 4 cm or smaller
- You cannot be on current cancer pills or other small-molecule cancer drugs when treatment starts
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial studies how PF-07799544 works and what dose is safest in people with advanced cancer that has a specific genetic change called BRAF V600. You may receive it alone or with another treatment, depending on the tumor group, to see if it can treat the cancer.
This Phase 1/2 study tests S241656 (a targeted cancer medicine) in people whose cancers have certain “RAS/RAF” gene changes. It may help shrink tumors or control cancer growth, and also finds the safest dose and best way to use the drug.
This trial tests a personalized approach where doctors monitor tumor DNA in your blood to decide when to pause targeted therapy (encorafenib and binimetinib) for advanced melanoma with a BRAF mutation. The goal is to see if treatment breaks can be safe and effective.
This trial tests a new drug called BI 3810944 for people with advanced solid tumors that haven't responded to standard treatments. It aims to see if the drug is safe and helps shrink tumors.
This trial tests cetuximab combined with dabrafenib and tislelizumab in people with advanced colorectal cancer that has a BRAF V600E mutation. It’s for cases where the first standard treatment didn’t work or couldn’t be tolerated, aiming to shrink tumors and improve control of the disease.
This trial tests a combination of three drugs (irinotecan liposomes, cetuximab, and vemurafenib) for people with advanced colorectal cancer that has a specific genetic change (BRAF V600E mutation) and did not respond to first treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Hear when a new Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.